171 related articles for article (PubMed ID: 35635647)
1. TPEN selectively eliminates lymphoblastic B cells from bone marrow pediatric acute lymphoblastic leukemia patients.
Mendivil-Perez M; Velez-Pardo C; Quiroz-Duque LM; Restrepo-Rincon A; Valencia-Zuluaga NA; Jimenez-Del-Rio M
Biometals; 2022 Aug; 35(4):741-758. PubMed ID: 35635647
[TBL] [Abstract][Full Text] [Related]
2. TPEN exerts selective anti-leukemic efficacy in ex vivo drug-resistant childhood acute leukemia.
Mendivil-Perez M; Velez-Pardo C; David-Yepes GE; Fox JE; Jimenez-Del-Rio M
Biometals; 2021 Feb; 34(1):49-66. PubMed ID: 33098492
[TBL] [Abstract][Full Text] [Related]
3. Combinational treatment of TPEN and TPGS induces apoptosis in acute lymphoblastic and chronic myeloid leukemia cells in vitro and ex vivo.
Mendivil-Perez M; Jimenez-Del-Rio M; Velez-Pardo C
Med Oncol; 2022 May; 39(7):109. PubMed ID: 35578067
[TBL] [Abstract][Full Text] [Related]
4. TPEN induces apoptosis independently of zinc chelator activity in a model of acute lymphoblastic leukemia and ex vivo acute leukemia cells through oxidative stress and mitochondria caspase-3- and AIF-dependent pathways.
Mendivil-Perez M; Velez-Pardo C; Jimenez-Del-Rio M
Oxid Med Cell Longev; 2012; 2012():313275. PubMed ID: 23320127
[TBL] [Abstract][Full Text] [Related]
5. TPEN Exerts Antitumor Efficacy in Murine Mammary Adenocarcinoma Through an H2O2 Signaling Mechanism Dependent on Caspase-3.
Soto-Mercado V; Mendivil-Perez M; Urueña-Pinzon C; Fiorentino S; Velez-Pardo C; Jimenez-Del-Rio M
Anticancer Agents Med Chem; 2018; 18(11):1617-1628. PubMed ID: 29697031
[TBL] [Abstract][Full Text] [Related]
6. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
[TBL] [Abstract][Full Text] [Related]
7. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F
Leukemia; 2008 Jun; 22(6):1207-13. PubMed ID: 18418410
[TBL] [Abstract][Full Text] [Related]
8. Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.
Uckun FM; Haissig S; Ledbetter JA; Fidler P; Myers DE; Kuebelbeck V; Weisdorf D; Gajl-Peczalska K; Kersey JH; Ramsay NK
Blood; 1992 Jun; 79(12):3369-79. PubMed ID: 1375851
[TBL] [Abstract][Full Text] [Related]
9. Metal chelator TPEN selectively induces apoptosis in K562 cells through reactive oxygen species signaling mechanism: implications for chronic myeloid leukemia.
Rojas-Valencia L; Velez-Pardo C; Jimenez-Del-Rio M
Biometals; 2017 Jun; 30(3):405-421. PubMed ID: 28409295
[TBL] [Abstract][Full Text] [Related]
10. [Proportions of cells expressing CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, or CD13,33+/CD34+ in the regenerating bone marrows during complete remission of acute leukemia or after bone marrow transplantation].
Kahng J; Shin SY; Han K
Korean J Lab Med; 2007 Dec; 27(6):406-13. PubMed ID: 18160830
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
[TBL] [Abstract][Full Text] [Related]
12. Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts.
Uckun FM; Song CW
Blood; 1993 Mar; 81(5):1323-32. PubMed ID: 8443393
[TBL] [Abstract][Full Text] [Related]
13. CD19 negative precursor B acute lymphoblastic leukemia (B-ALL)-Immunophenotypic challenges in diagnosis and monitoring: A study of three cases.
Ghodke K; Bibi A; Rabade N; Patkar N; Subramanian PG; Kadam PA; Badrinath Y; Ghogale S; Gujral S; Tembhare P
Cytometry B Clin Cytom; 2017 Jul; 92(4):315-318. PubMed ID: 27018867
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.
Lúcio P; Parreira A; van den Beemd MW; van Lochem EG; van Wering ER; Baars E; Porwit-MacDonald A; Bjorklund E; Gaipa G; Biondi A; Orfao A; Janossy G; van Dongen JJ; San Miguel JF
Leukemia; 1999 Mar; 13(3):419-27. PubMed ID: 10086733
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity.
Zanetti SR; Romecin PA; Vinyoles M; Juan M; Fuster JL; Cámos M; Querol S; Delgado M; Menendez P
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868394
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the CD10+CD19+CD34+ B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group.
Uckun FM; Sather H; Gaynon P; Arthur D; Nachman J; Sensel M; Steinherz P; Hutchinson R; Trigg M; Reaman G
Leuk Lymphoma; 1997 Nov; 27(5-6):445-57. PubMed ID: 9477126
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD10, CD19 and CD34 markers in bone marrow samples of children with precursor B-cell acute lymphoblastic leukemia in clinical and hematological remission.
Cáp J; Babusíková O; Kaiserová E; Jamárik M
Neoplasma; 1998; 45(4):231-6. PubMed ID: 9890666
[TBL] [Abstract][Full Text] [Related]
18. Lymphoblastic lymphoma.
Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
[TBL] [Abstract][Full Text] [Related]
19. [Immunophenotyping of leukemic stem cells and chromosome karyotype characteristics in Uyghur leukemia pediatric patients].
Hailiqiguli N; Yan M
Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):501-4. PubMed ID: 24257300
[TBL] [Abstract][Full Text] [Related]
20. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
